Torrent Pharmaceuticals on Wednesday reported a 0.99 per cent quarter-on-quarter (QoQ) decline in its net profit for the ...

Torrent Pharmaceuticals posted a steady set of numbers in the fourth quarter, reinforcing confidence in its growth trajectory ...

Prabhudas Lilladher recommended accumulate rating on Torrent Pharmaceuticals with a target price of Rs 3670 in its research ...

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as ...

Net Sales at Rs 2,433.00 crore in March 2025 up 13.53% from Rs. 2,143.00 crore in March 2024. Quarterly Net Profit at Rs. 474.00 crore in March 2025 up 15.61% from Rs. 410.00 crore in March 2024.

Aman Mehta, third generation of Torrent Group’s founder Mehta family, was on Tuesday appointed Managing Director of the ...

Torrent Pharma's US business is set to benefit from new launches and stronger growth momentum, while Germany is likely to see ...

Dixon Technologies, NHPC , Hindalco, Gland Pharma and Torrent Pharmaceuticals Ltd and United Spirits Limited are among 6 key ...

The yield on the 10-year bond opened flat at 6.27% ...

Morgan Stanley believes India's fundamentals remain strong, supported by macro stability, improving terms of trade, declining ...